Lilly's Omvoh meets primary endpoint of clinical remission in pediatric ulcerative colitis
In the single-arm, open-label Phase 3 SHINE-2 study, 81% of 63 pediatric patients achieved clinical response at Week 12 and 50% of responders were in clinical remission at Week 52, meeting the study's primary endpoint. The safety profile through Week 52 was consistent with that seen in adults, with no new safety signals reported.
Primary source
Company press release (PR Newswire), October 19, 2026
Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis
Machine-summarized from the source above; not independently reported. How we use automation